Gastritis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Gastritis – Pipeline Review, H1 2020’, provides an overview of the Gastritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gastritis

– The report reviews pipeline therapeutics for Gastritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gastritis therapeutics and enlists all their major and minor projects

– The report assesses Gastritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gastritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gastritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addpharma Inc

Allakos Inc

CalyGene Biotechnology Inc

GNT Pharma Co Ltd

Kyowa Kirin Co Ltd

Otsuka Holdings Co Ltd

Recce Pharmaceuticals Ltd

RedHill Biopharma Ltd

Trio Medicines Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastritis - Overview

Gastritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gastritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastritis - Companies Involved in Therapeutics Development

Addpharma Inc

Allakos Inc

CalyGene Biotechnology Inc

GNT Pharma Co Ltd

Kyowa Kirin Co Ltd

Otsuka Holdings Co Ltd

Recce Pharmaceuticals Ltd

RedHill Biopharma Ltd

Trio Medicines Ltd

Gastritis - Drug Profiles

AAD-2004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-20043 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rebamipide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RECCE-327 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastritis - Dormant Projects

Gastritis - Product Development Milestones

Featured News & Press Releases

May 04, 2020: Allakos announces positive interim results from an open-label extension study of Antolimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis

Apr 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the 2020 DDW Annual Meeting

Mar 24, 2020: Allakos announces positive phase 1 results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)

Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results

Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting

Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis

Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Gastritis, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Gastritis – Pipeline by Addpharma Inc, H1 2020

Gastritis – Pipeline by Allakos Inc, H1 2020

Gastritis – Pipeline by CalyGene Biotechnology Inc, H1 2020

Gastritis – Pipeline by GNT Pharma Co Ltd, H1 2020

Gastritis – Pipeline by Kyowa Kirin Co Ltd, H1 2020

Gastritis – Pipeline by Otsuka Holdings Co Ltd, H1 2020

Gastritis – Pipeline by Recce Pharmaceuticals Ltd, H1 2020

Gastritis – Pipeline by RedHill Biopharma Ltd, H1 2020

Gastritis – Pipeline by Trio Medicines Ltd, H1 2020

Gastritis – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Gastritis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports